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ABSTRACT 
Previous work has shown that S44819 is a novel GABAA receptor (GABAAR) antagonist, which is 
selective for extrasynaptic GABAARs incorporating the α5 subunit (α5-GABAARs). The present 
study reports on the preclinical neuropsychopharmacological profile of S44819. Significantly, no 
sedative or pro-convulsive side effects of S44819 were found at doses up to 30 mg/kg i.p.. Object 
recognition (OR) memory in intact mice was enhanced by S44819 (0.3 mg/kg p.o.) given before 
the acquisition trial. Mice treated with phencyclidine for two weeks and tested six days after the 
cessation of treatment failed to show OR memory. This deficit was corrected by a single 
administration of S44819 (0.1, 0.3 or 1 mg/kg p.o.) prior to the acquisition trial. The amnestic effect 
of ketamine in rats tested in the eight-arm radial maze (reference and working memory versions) 
was blocked by S44819 (3 mg/kg p.o.). Extinction of cued fear was preserved during treatment 
with S44819 (3 mg/kg/diem i.p.). Administration of S44819 had no significant effect in the Vogel-
conflict test, the elevated plus maze, the forced swim, the marble-burying and the tail-suspension 
tests. In contrast, anxiolytic/antidepressant-like effects of the compound were found in paradigms 
that have mnemonic components, such as social interaction, fear-potentiated startle and social 
avoidance induced by negative life experience. In summary, S44819 enhanced intact recognition 
memory and ameliorated memory deficits induced by inhibition of NMDA receptors. 
Anxiolytic/antidepressant efficacy was limited to paradigms involving cognitive function. In 
conclusion, S44819 is a novel psychoactive pro-cognitive compound with potential as a therapeutic 
agent in dementia. 
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1. Introduction 
 
Gamma-aminobutyric acid (GABA) is a fundamentally important neurotransmitter in the CNS 
(Klausberger and Somogyi, 2008; Walker, 1983). The actions of GABA are mediated by ionotropic 
GABAA (GABAARs) and metabotropic GABAB receptors. The topographical distribution of GABAAR 
subunits in the brain indicates non-redundant functions (Pirker et al., 2000; Wisden et al., 1992). 
Indeed, in a pioneering studies analysing genetically engineered mice, the groups of Rudolph and 
Möhler and of McKernan and Whiting (reviewed by (Rudolph and Möhler, 2014)), showed that the 
diverse effects of diazepam on brain function were attributable to GABAARs incorporating specific 
α-subunits. These studies were the first to show that α5-GABAARs influence cognitive functions. 
Thus, the physiologic rationale of producing GABAA isoform selective pharmacons as therapeutic 
agents was established (Dawson et al., 2005). 
 
The chemical synthesis and biological characterization of a family of tricyclic compounds, based on 
a 2,3-benzodiazepine scaffold, that are competitive inhibitors of GABA binding at the α−β subunit 
interface, was previously reported (Etherington et al., 2017; Ling et al., 2015). For some 
compounds, orthosteric antagonism was paired with inhibition of Cl--channel gating, similar to the 
properties of the GABAAR antagonist, bicuculline (Ueno et al., 1997). However, in contrast to 
bicuculline, which is a non-selective blocker of most GABAAR isoforms, some of the novel 
compounds show considerable isoform selectivity. A potentially valuable compound in the series is 
S44819, which is a largely selective inhibitor of extrasynaptic α5-GABAARs in vitro (Etherington et 
al., 2017). The current paper reports the in vivo preclinical pharmacology of this molecule.  The 
results show enhancement of normal as well as remediation of impaired cognitive function, 
including object recognition memory, spatial working and reference memory by S44819. The 
compound also showed significant anxiolytic/antidepressant-like activity in tests that have a 
mnemonic component.  
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2. Methods 
 
2.1  Animals 
Male rats (190–270 g BW), or mice (20-30 g BW) — the strains are specified under the headings 
of the respective tests — were housed under standardized laboratory conditions (24 ± 2 ºC, 40–
60% relative humidity), on a 12-h light/dark cycle with light onset at 6:00 AM. All experimental 
protocols were approved by the Animal Care and Use Ethical Committee of Egis Pharmaceuticals 
PLC and complied with the Hungarian Law of Animal Care and Use (1998. XVIII).  
 
2.2 Compounds 
S44189 (Egis-13529), substituted 8-methyl-5-[1-benzothiophen-2-yl]-1,9-dihydro-2H-[1,3]oxazolo [4,5-
h][2,3]benzodiazepin-2-one was produced as free base at greater than 97% purity at Egis 
Pharmaceuticals PLC as previously described (Ling et al., 2012; Ling et al., 2015). The solubility of 
the compound in physiological buffers containing 0.1% DMSO (v/v) was around 50 µM. 
Furthermore, because of the poor oral bioavailability of S44819 (F < 2%) the compound had to be 
micro-formulated for preclinical studies. Two formulations of S44819 were provided by Dr Caroline 
Chemin, Technologie Servier, (Orleans, France). The first, Aqoat, was a suspension of micro-
milled S44819/Hypromellose Acetate Succinate (Shin Etsu Chemical Co, Japan)/Magnesium 
stearate (30/69.5/0.5, w/w/w) suspended in 2% (w/v) hydroxy-ethylcellulose (Molar Chemicals Ltd, 
Budapest). The second, (nanoF3) was a nano-encapsulated formulation consisting of S44819 
3.85/Lipoïd S100 (Lipoïd GmbH, Ludwigshafen, Germany) 38.5/trehalose 57.7, w/w/w). Both 
formulations were used for intra-peritoneal (i.p.) as well as oral (p.o.) administration. The 
preparations were administered on the basis of their free base active product ingredient content. 
An effort was made to minimize the exposure of the animals to the excipients.  Thus, the amount of 
excipient used depended on the highest dose of the drug administered in a given experiment — 
importantly, the dose of excipient was kept constant within a particular study. The highest dose of 
S44819 formulated with Aqoat was 30 mg/kg, thus all animals in received 0.50 mg/kg magnesium 
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stearate, 71 mg/kg hypromellose acetate succinate and 0.1 mg/kg of hydroxy-ethylcellulose. The 
dose of excipients was kept constant with reduced doses of drug. In the case of nanoF3, the 
highest dose used was 30 mg/kg of S44819, thus the animals also received 300 mg/kg Lipoïd 
S100 and 450mg/kg of trehalose. The dose of excipients was kept constant with reduced doses of 
drug. The drug administration regimes described below were optimized on the basis of preliminary 
kinetic studies in mice and rats with both formulations of S44819.  Notably, both formulations gave 
similar brain:plasma concentration ratios approximating 1:2 in male mice (see Suppl. Fig.-s 1 and 
2) and 1:4 in male rats (data not shown). 
 
2.3 Object recognition assay in mice 
Male albino NMRI mice bred in house were used. The experimental protocol was analogous to that 
described for rats (Gacsályi et al., 2013). Briefly, Day 0, familiarization: mice spent 2.5 minutes in a 
24 x 34 x 24 cm box with black plastic walls. Acquisition: on the next day mice were allowed to 
explore freely two identical objects placed symmetrically at 4-4 cm from the shorter sides of the 
box. The animals were removed from the box when exploration times of both objects reached 10 
s/object during a maximum 5 min period. Retention: 24 h later the animals were allowed to explore  
a novel object and an identical copy of the familiar object — the exploration time for both objects 
was recorded for 4 min. Treatment with Aqoat-formulated S44819 (0.03, 0.1, 0.3 mg/kg), or vehicle 
was performed p.o. 120 min before the start of the acquisition trial. Data were analysed by one-
way analysis of variance followed by Dunnett's multiple comparison test. 
 
In another series of experiments NMRI mice were subjected to sub-chronic treatment with vehicle 
(0.9% w/v NaCl), or phencyclidine (PCP, supplied by Tocris, U.K.): 3 mg/kg i.p. twice a day for a 
total of ten days (2x 5 days with a two-day break). Six days after the last PCP treatment, S44819 
at 0.1, 0.3 and 1 mg/kg was administered p.o. 120 min before the start of the acquisition trial. The 
study protocol was exactly the same as above, except that the retention trial took place 15 min 
after the start of the acquisition period. Animals were returned to their home cage between the 
acquisition and retention trials. Data were analysed by Student’s t-test to validate the effect of PCP 
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(control vs. vehicle i.e. 0 mg/kg S44819-group) and one-way ANOVA followed by Dunnett's 
multiple comparison test (vehicle vs. S44819-treated groups) to assess the effect of S44819.  
 
 
2.4 Working memory in the eight-arm radial maze in rats 
 
Male Lister-Hooded rats 185-228 g body weight (Harlan Laboratories, The Netherlands) were 
trained and tested in an eight-arm-maze-based spatial working memory task in a dimly lit special 
room where geometric shapes were placed on the walls as visual cues. (Gacsályi et al., 2013). 
The maze was constructed from Perspex. It consisted of a central octagonal platform (diameter: 28 
cm) and 8 radial direction arms (width: 9.5 cm, length: 70 cm, wall height: 12 cm). The central part 
and the arms had removable Perspex covers. Bait-food (5 mm diameter pellets made from a 
mixture (1:1, w/w) of ground tea-biscuits (Győri Otthon Keksz, Tesco stores, Budapest) and instant 
cocoa powder (Nesquik, Nestlé, Tesco stores)) was placed in a cavity at end of the arms. It was 
verified in previous independent studies, that the animals used the visual cues to find the bait. 
Young adult male Lister-Hooded rats were handled daily by the experimenter and were relatively 
food-deprived receiving approximately 8-10 g standard rodent food/day/animal per day. Training 
continued for 13 days (suspended on weekends). Rats were placed onto the central platform of the 
maze with all 8 arms baited. Rats were allowed to eat the bait from all 8 arms. If the rat did not eat 
all of the baits within 20 min it was removed from the maze. The following parameters were 
recorded. Repetition error (RE) is visiting the same arm more than once, Initial correct responses 
(ICR) is number of correct entries until first error. Animals included in the study had RE values <3 
or ICR ≥7. On the last day of the experiment (after 13 days training) animals were given vehicle, or 
Aqoat-formulated S44819 p.o. (0.3, 1 and 3 mg/kg) and ketamine 10 mg/kg i.p., at 120 and 30 min 
before the start of the trial, respectively. A single trial lasted a maximum of 5 min. The numbers of 
RE-s were analyzed by non-parametric Mann-Whitney test (intact control vs. ketamine control 
group) and Kruskal-Wallis test, followed by Dunn’s multiple comparison test (ketamine control 
group vs. ketamine + different S44819 doses) 
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2.5 Reference memory in the eight-arm radial maze in rats  
Reference memory was studied in male Lister-Hooded rats 230-310 g body weight with the same 
equipment and protocol as working memory (described above) with the following modifications. 
Only four arms out of eight were baited in the training sessions. Baiting was arranged in ten 
different configurations to the eight arms, a given animal was trained on the same configuration of 
arms throughout the entire experiment. Rats were allowed to eat the bait from all 4 arms. If the rat 
did not consume all the baits within 20 min it was removed from the maze. Training runs were 
performed once a day for 18 days (excluding weekends). On the last day of the experiment (after 
18 days training) the animals were given vehicle, or Aqoat-formulated S44819 (0.3, 1 and 3 mg/kg, 
p.o.) and ketamine 10 mg/kg i.p., at 120 and 30 min before the start of the trial, respectively. The 
numbers of errors, i.e. the number of entries into arms that had never been baited and the number 
of the missed baited arms within the 5 min of testing, were recorded. Inclusion criteria: 1) the rat 
performs perfectly at least once in the last 3 learning days within 5 min, or 2) the rat has less than 
3 errors, or makes a mistake after the 3 correct entries in the last learning day in 5 or less minutes. 
The numbers of errors were analyzed by the Mann-Whitney U-test and the Kruskal-Wallis ANOVA 
followed by Dunn's multiple comparison test. 
 
2.6 Extinction of cued fear 
 
The subjects were male young adult C57BL/6J mice (20-25 g BW, Charles River, Germany). 
Apparatus: TSE Fear Conditioning System (TSE System GmbH, Bad Homburg, Germany), four 
animals were tested simultaneously. The protocol is summarized in Fig.5. Fear conditioning (Day 
1): Mice were placed into the test chambers (21.5 cm x 21.5 cm x 35 cm) and after 3 min 
habituation were given the first of 3 noise/foot-shock pairings. The 0.7 mA, 2 s electric shock was 
delivered during the last 2 s of the 30 s exposure to white noise (85 dB). The average inter-trial 
interval was 2 min. Extinction procedure (Days 2 - 5): Twenty four h after the last trial, S44819 (3 
mg/kg, nanoF3 formulated), or vehicle was administered i.p. each day 30 min before the start of 
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the extinction session. Mice were then placed into the same chamber where they received the 
conditioning and after 3 min habituation, were exposed to 4 x 30 s of white noise (85 dB) – inter-
trial intervals were 60 s. The number of freezing reactions was recorded. The reaction was 
considered freezing if the mouse was immobile for a minimum 2 s. Freezing was scored by 
dividing the 30 s noise stimulus into 5 s bins. If the animal froze in all 6 bins it received a score of 
6.  Four noise stimuli were given in total and the percentage of bins in which freezing was evident 
was calculated for each animal. Data were analyzed by one-way ANOVA followed by Dunnett’s 
test for multiple comparisons. 
 
2.7 Fear potentiated startle response test in rats 
Male Sprague-Dawley rats bred in house were used. The fear potentiated startle procedure (Davis 
et al., 1993; Walker and Davis, 1997) also see Suppl. Fig. 11, consisted of learning, pre-test and 
test periods. In the learning period over two consecutive days, male Sprague-Dawley rats were 
placed into the test chambers and 5 min later given the first of 10 light/foot-shock pairings. The 1 
mA, 0.5 s shock was delivered during the last 0.5 s of the 3.7 s light pulse. The average inter-trial 
interval (ITI) was 3 min. Background noise: 55 dB. Twenty-four h after the learning period, rats 
were returned to the test chambers for the pre-test phase. Five min later 10 x 95 dB noise bursts 
(ITI: 20-40 s) were presented (habituation). After 30 s, 3 noise alone stimuli (95 dB) and 3 noise + 
light stimuli were presented. On the test day (24 h after the completion of pre-test) the rats were 
returned to the test chambers and 5 min later were presented with the same initial habituation 
noise. 30 s later 10-10 noise alone (95 dB) and noise + light stimuli in random order were 
presented to the animal. The calculated parameter is the difference in the magnitude of startle 
responses between “light + noise” and “noise alone” trials. (Difference = magnitude of startle 
response at “light-noise” trials – magnitude of startle response at “noise alone” trials). Acute 
treatment with vehicle, or S44819 (nanoF3, 1, 3 and 10 mg/kg i.p.), was on the test day 30 min 
before the trial. The positive control diazepam was administered acutely at 3 mg/kg, i.p. 30 min 
before the test. Data were analyzed by one-way ANOVA followed by Dunnett’s test for multiple 
comparisons.  
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2.8 Social interaction in rats 
 
The study was carried out on 60 male Wistar rats (Charles River Laboratories, Hungary) 190-210 
g body weight. After their arrival in the animal facility, rats were housed in groups of four in cages 
measuring 45 x 30 x 20 cm. One week of habituation to local conditions was allowed. Rats were 
familiarized with the test apparatus by being placed individually into the test arena for 10 min on 
the last two days of the habituation. Rats were weighed on the last habituation day. Experiments 
were performed in two sessions on two consecutive days. Treatments were balanced over 
sessions. Pharmacological treatments were performed one day after the last individual exposure 
to the test arena, during the first half of the dark phase. The effects of vehicle and S44819 
(nanoF3, 1 ,3 10 mg/kg i.p.) were compared together with 10 mg/kg chlordiazepoxide (CDP) as 
reference. Sample size was 12, but one pair was discarded from the chlordiazepoxide group for 
technical reasons. Therefore, the sample size was 10 in this group. Pairs of rats were placed in 
the test arena (60 x 50 x 40 cm) 30 min after drug treatment and observed for 10 min. The 
members of the pairs were unfamiliar to each other and received the same pharmacological 
treatment. Behavior was video-recorded through the transparent front wall of the test cage and 
later analyzed by means of a computer-based event recorder by an experimenter blind to the 
drug treatment regimen. The social interaction test arena was a dark grey plastic box of 40 x 60 x 
50 cm with wood shaving bedding. Boxes were lit by white light. The front wall of the box was of 
transparent plastic. Six boxes were used in parallel. Fresh bedding was used for each pair of rats. 
The duration and the frequency of social interactions (sniffing partner; anogenital sniffing; 
following; allogrooming) and total amount time spent moving around the arena (exploration) were 
recorded. An increase in social interactions is consistent with an anxiolytic action. Increased 
resting and decreased exploration were considered signs of sedative or locomotor suppressive 
effects. The parameter analysed was the amount of time engaged in social interaction expressed 
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as a percentage of the total exploration time. Data were analyzed by Kruskal-Wallis ANOVA. The 
Mann-Whitney test was used for post-hoc comparisons.  
 
 
2.9 Social avoidance induced by electric shock 
The test was carried out in young male Wistar rats (7-9 weeks old, 250-350 g body weight) as 
previously reported (Leveleki et al., 2006; Sziray et al., 2007). Briefly, inescapable electric shocks 
(24 shocks, 3 mA, 1 s duration, 29 s interval) were delivered 1 day before the social avoidance test 
via the grid floor. Twenty-four h later, the social avoidance testing was performed in a different box 
from the one in which the foot shocks were delivered. Animals were injected i.p. with S44819 
(nanoF3 0.3 and 1 mg/kg), or vehicle 30 min before the test. The subject was placed in a cage (16 
x 52 cm) for a 3 min habituation period upon which a sliding door leading to a larger cage (40.5 x 
41 cm) was opened. The larger cage was divided into two equal (40.5 cm x 20.5 cm) 
compartments by a transparent, perforated plastic wall running down the middle. The distant 
compartment contained a large, unfamiliar male Wistar rat (>11 weeks old, >400 g body weight), 
as the opponent. The opponent was un-shocked. The subject was allowed to explore the resulting 
space for 5 min. The test apparatus did not permit physical contact between the experimental and 
stimulus animals. The duration of visits made to the middle compartment (opponent time) was 
recorded and expressed as percentage of the total time of exploration (% opponent time). Data 
were analyzed by one-way ANOVA followed by Dunnett’s test for multiple comparisons. 
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3. Results 
 
Analysis of spontaneous locomotor activity (see Supplementary methods) indicated that nano-
formulated S44819 had no sedative, or anxiogenic actions at doses up to 30 mg/kg i.p. (Fig. 1A). 
Further tests of anxiety were in agreement with this conclusion (Suppl. Figs. 4-7). Moreover, there 
were no signs of muscle weakness/relaxation in the inclined screen test at doses up to 100 mg/kg 
in marked contrast with Baclofen and Diazepam at 10ml/kg, i.p. both of which had a significant 
effect on muscle strength (Suppl. Fig. 3).  Non-selective inhibition of GABAA receptors results in 
the lowering of the convulsion threshold (Stephens and Turski, 1993). This was indeed the case 
upon chronic administration of pentylenetetrazole (40 mg/kg i.p, see Supplementary methods): by 
day 18, 60 % of the animals displayed clonic seizures (Fig.1B). In contrast, there were no signs of 
seizures in the group given the same dosage of S44819 (Fig.1B). 
 
3.1 Novel object preference in mice 
 In intact male mice, acute administration of Aqoat formulated S44819 at 0.3 mg/kg p.o., given 120 
min prior to the acquisition trial, significantly increased the time spent investigating the novel object 
over the familiar object 24 h after acquisition (Fig. 2). Note that in this study the time for object 
exploration and the inter-trial interval were adjusted so that the control animals had no significant 
retention of the object explored during the acquisition trial. Other dosage regimes of the drug were 
not tested.  
The effect of S44819 on PCP-induced memory deficit was also examined. As reported previously 
by others (Grayson et al., 2007; Redrobe et al., 2010), mice subjected to sub-chronic treatment 
with PCP failed to show significant short-term object recognition memory (Fig. 3). Acute 
administration of S44819 at 0.1, 0.3 and 1 mg/kg, p.o. 120 min before the acquisition trial fully 
restored recognition memory in a dose-dependent manner (Fig. 3). 
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3.2 Remediation of ketamine-induced impairments of working and reference memory in the eight-
arm radial maze in rats 
Male rats were tested in the eight-arm maze in order to assess the effect of S44819 (0.3, 1 and 3 
mg/kg, p.o.) in cognitive disruption induced by ketamine. Indeed, acute administration of ketamine 
(10 mg/kg) produced significant deterioration of working, as well as reference memory in the eight-
arm radial maze (Fig. 4A & B). Acute administration of S44819 (Aqoat, 0.3 - 3 mg/kg p.o. 120 min 
before the trial) improved performance in both paradigms with 3 mg/kg being close to maximally 
effective.   
 
3.3 Extinction of cued fear in mice 
It has been reported that synaptic plasticity in the form of LTD, in addition to LTP are important for 
the extinction of cued fear (Myers and Davis, 2006; Nabavi et al., 2014). As S44819 facilitated 
hippocampal CA1 neuron LTP (Etherington et al., 2017) and as α5-GABAARs may facilitate LTD 
(Martin et al., 2010), it was of interest to test whether or not S44819 had any effect on the 
extinction of cued fear by causing an imbalance of neuronal plasticity favouring LTP. The effect of 
S44819 on the extinction of cued fear was tested at 3 mg/kg daily, i.p. in mice (Fig. 5). Fear 
extinction was observed in vehicle as well as the S44819 treated groups. While in the control 
group the decrement in freezing behavior was significant only on day 5, in the S44819 treated 
groups there was a significant reduction on days 4 and 5. Taken together, S44819 (3mg/kg daily) 
had no deleterious effects on the extinction process, if anything, a small degree of enhancement of 
fear extinction was apparent on day 4.   
 
3.4 Fear potentiated startle in rats 
The potentiation of acoustic startle reflex by experimentally induced fear has been used as a 
preclinical surrogate of general anxiety disorder (Davis et al., 1993). As recent reports have 
suggested that α5-GABARs could mediate the anxiolytic effects of endogenous GABA (Behlke et 
al., 2016; Botta et al., 2015), an antagonist of these receptors, such as S44819 may prove to be 
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anxiogenic.  Importantly, treatment with S44819 at 1 and 3 mg/kg produced a marked reduction of 
the enhancement of the startle response by the conditional light-pulse stimulus (Fig. 6), whereas 
no significant effect was observed at 10 mg/kg (Fig. 6). The compound (up to 10 mg/kg) had no 
effect of the basal startle reflex (data not shown). The reference anxiolytic compound diazepam 
(3mg/kg, i.p.) also significantly decreased the fear potentiated startle response of rats. 
 
3.5 Social avoidance upon (electric shock) in rats 
This test is a long-term model of social anxiety induced by a negative experience, which is 
sensitive to anxiolytic and anti-depressant drugs (Leveleki et al., 2006). A train of electric foot-
shocks produced a significant level of social avoidance 24 h later (Fig. 7). Administration of 
S44819 (nanoF3, 0.3-1 mg/kg i.p.) 30 min before the social avoidance trial reversed the effect of 
prior electric shock (Fig. 7).  
 
3.6 Social interaction in rats 
The social interaction paradigm is used to evaluate the level of spontaneous anxiety in laboratory 
rodents. In male Wistar rats, the amount of time engaged in social interactions was dose-
dependently enhanced by S44819 (1-10 mg/kp i.p.) (Fig. 8A). The lowest effective dose was 1 
mg/kg i.p. (Fig. 8A). Importantly, no effect on exploration time was apparent for S44819 at doses 
up to 10 mg/kg (Fig. 8B). The effect of S44819 was equivalent to that produced by CDP (10 mg/kg 
i.p.), but note, that in contrast to S44819, CDP at this dose decreased the exploration time, i.e. had 
a sedative effect.  
 
4. Discussion and conclusions 
The data presented here demonstrate that S44819 can enhance normal learning and memory as 
well as ameliorate the impairment of these processes induced by acute, or sub-chronic inhibition of 
NMDA receptors by ketamine and PCP, respectively.  Given the effects of S44819 to improve 
learning and memory, it was important to analyze its efficacy in tests of anxiety, fear and 
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depression. The results of the latter group of studies demonstrated that the anxiolytic efficacy of 
S44819 was manifested in paradigms that engaged a cognitive component in the behavior. 
 
An extensive body of evidence has accumulated showing that a reduction of α5-GABAAR function 
by pharmacological or genetic methods, improves cognitive performance in a variety of paradigms 
(Atack, 2011; Rudolph and Möhler, 2014). The pharmacons previously studied in this respect were 
all benzodiazepine site NAMs (Atack, 2011; Ballard et al., 2009; Chambers et al., 2003). In 
principle, S44819, a novel competitive blocker of α5-GABAARs (Etherington et al., 2017) offers a 
potentially important advantage over α5-GABAAR NAMs. Due to the relatively low affinity for its 
target, S44819 is likely to block the activation of extrasynaptic α5-GABAARs exposed to maximally 
1 µM of GABA, but to be largely ineffective against the high concentrations of GABA that occur in 
the synaptic cleft (Etherington et al., 2017; Ling et al., 2015). In contrast, α5-GABAAR NAMs 
reduce the activity of synaptic (Salesse et al., 2011) as well as extrasynaptic α5-GABAARs 
(Caraiscos et al., 2004; Glykys et al., 2008; Martin et al., 2010). Importantly, as expected of an α5-
GABAAR selective GABAA antagonist (Dawson et al., 2006) and in contrast to non-selective 
inhibitors of GABAA receptors, S44819 had no sedative or pro-convulsive effects. 
 
The current study demonstrated the improvement of cognitive performance by S44819 in a variety 
of experimental paradigms. Long-term object recognition memory could be enhanced by S44819 in 
intact mice (present study) as well as rats (Etherington et al., 2017). Furthermore, similar to the 
effect of an α5-GABAA NAM in rats (Redrobe et al., 2012), the dramatic impairment of object 
recognition memory induced by subchronic PCP treatment of mice was reversed by acute 
treatment with S44819. Acute treatment with S44819 also improved declarative and working 
spatial memory disrupted by ketamine. Previously, it was also found to be effective against 
impairments of working memory induced by scopolamine (Etherington et al., 2017). Collectively, 
these results militate for actions of S44819 in the hippocampal gyrus and the neocortex. Indeed, 
previous work has shown that S44819 reduces tonic inhibition and potentiates LTP induced by a 
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theta-burst stimulation protocol in mouse CA1 pyramidal neurons (Etherington et al., 2017) and 
enhances the excitability of neurons in the M1 region of the human motor cortex (Darmani et al., 
2016). 
 
The outcomes of preclinical assays of cognitive performance may be markedly influenced by 
changes in the levels of learned and innate fear, or anxiety. Thus, we have examined the effect of 
S44819 in standard assays of anxiety and depression (see Suppl. Fig.-s 3-9). These studies 
revealed that S44819 was essentially without effect in these assays, except for the light-dark box 
paradigm where it had a significant anxiolytic effect at 30 mg/kg (Suppl. Fig. 5). In less standard 
assays, such as fear-potentiated startle, social interaction, and social avoidance induced by 
traumatic stress, the compound proved to be effective. Both fear-potentiated startle (Davis et al., 
1993) and social interaction (File and Seth, 2003) are sensitive to the acute administration of 
anxiolytics such as diazepam and buspirone. However, in considering the interaction with the 
GABAAR, S44819 is distinct from 1,4-benzodiazepines, being a competitive antagonist of the 
GABA recognition site (Etherington et al., 2017). Moreover, it shows no appreciable effect on any 
of the receptors known to interact with buspirone. Classic antidepressant compounds such as 
fluoxetine are anxiogenic when given acutely in the fear-potentiated startle, as well as the social 
interaction paradigms (Davis et al., 1993; File and Seth, 2003). It is clear that social-interaction 
involves early learning and memory experience that is recalled during the test (File and Seth, 
2003), and may be facilitated by S44819. Fear-potentiated startle has an element of conditioned 
fear and anatomically involves the central amygdala (Davis et al., 1993; Walker and Davis, 1997). 
The facilitation by S44819 of cognitive surveillance of the conditioned stimulus-association could 
contribute to the reduction of startle amplitude. Furthermore, recent work has highlighted the 
involvement of tonic, α5-GABAAR mediated inhibition in regulating the activity of PKCδ expressing 
neurons in the central amygdala (Botta et al., 2015), which is a key brain site for fear conditioning 
(Ciocchi et al., 2010). Thus it cannot be excluded, that in addition to effects on cognitive 
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performance, neurons of the central amygdala are also substrates of the action of S44819 in the 
fear-potentiated startle paradigm. 
 
Social avoidance produced by the single traumatic stress model described here, is diminished by 
antidepressants such as fluoxetine (Leveleki et al., 2006; Sziray et al., 2007). A rapid anti-
depressant-like action of α5-GABAA NAMs to reduce social avoidance in animals subjected to 
chronic stress paradigms has been recently reported (Fischell et al., 2015). The efficacy of these 
compounds has been ascribed to the restoration of reduced AMPA receptor mediated synaptic 
transmission in the temporoammonic-hippocampal CA1 pathway (Fischell et al., 2015). Similar to 
other α5-GABAAR inhibitors, S44819 enhanced theta-burst long-term potentiation in the CA1 area 
(Etherington et al., 2017). Thus, the parsimonious explanation for the efficacy of S44819 in social 
avoidance induced by traumatic stress is the potential for a dual mechanism of action at the level 
of associative memory as well as the affective filters in the amygdala resulting in the improvement 
of the behavioural response to stress. However, recent data (Botta et al., 2015) indicate, that by 
altering the excitability of neurons expressing α5-GABAAR in the central amygdala, S44819 could 
also directly influence affective components of behaviour warranting further studies in this area. 
   
In summary, we have demonstrated the enhancement as well as remediation of learning and 
memory by S44819 in several cognitive domains. The compound did not produce the side effects 
such as sedation, muscle weakness or pro-convulsive symptoms, which are characteristic of non-
selective enhancers of GABA action. We also found that the S44819 has efficacy in preclinical 
assays of anxiety and traumatic stress that all have mnemonic components, i.e. the anxiolytic/anti-
depressant-like efficacy of S44819 could be secondary to the facilitation of cognitive processes. 
Notably, S44819 has been shown to alter the EEG response to transcranial magnetic stimulation in 
humans (Darmani et al., 2016) and is now in Phase 2 clinical trials 
(https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001005-16/HU). 
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LEGENDS TO THE FIGURES 
Fig. 1 A) No appreciable effect of S44819 (nanoF3, up to at 30 mg/kg i.p) on 
spontaneous motor activity. Data are mean ± S.E.M. n=8/group. B) No apparent 
kindling effect of 40 mg/kg i.p. S44819 (nanoF3) in male NMRI mice after up to 19 
days of treatment.  Note prominent epileptogenic kindling by pentylenetetrazole 
(see Supplement for methods).  n=10/group.  
Fig. 2 Object recognition memory is enhanced by S44819 in intact NMRI mice. The test trial 
with the new object was carried out 24 h after the acquisition trial with two identical 
objects.  S44819 (Aqoat) was given p.o. 120  min before the acquisition trial.  The 
discrimination index (DI) is shown where N is the time spent inspecting the new 
object, F is the time spent exploring  the familiar object during the test trial.  Data 
are mean ± S.E.M. n=10/group.  ** P<0.01  one-way ANOVA  followed by Dunnett’s 
test vs. vehicle (0 mg/kg) group.  
Fig. 3 Reversal by S44819 of the impairment of object recognition memory induced by sub-
chronic treatment with PCP.   NMRI mice were treated with saline or PCP 3 mg/kg 
twice daily i.p. for 2 x 5 days with a two-day pause between the two courses of 
treatment.  Ten days after the last treatment with PCP object recognition memory 
was tested by examining novel object preference in the two-object version of the 
test. The test trial took place 15 min after the acquisition trial.  Treatment with 
S44819 or vehicle (Aqoat, p.o.) was 120  min before the onset of acquisition.  Data 
are mean ± S.E.M. n=10/group. ### P<0.001 Student’s t-test vs Control (CTRL) 
group subchronically treated with saline and acutely receiving vehicle. ** P<0.01 
***P<0.001 one-way ANOVA  followed by Dunnett’s test vs vehicle (0 mg/kg) group 
with had received PCP.  
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Fig. 4 The acute disruptive effect of 10 mg/kg ketamine on spatial reference (A)  and 
working (B) memory is opposed by S44819.  A) Male Lister-Hooded rats were 
trained to criterion  in the eight-arm radial maze for 13 days to retrieve bait placed in 
four of the arms.  On the day of the test trial the animals received vehicle or  S44819 
(Aqoat,  0.3, 1, 3 mg/kg p.o. )  120  min prior to the start of the test. They were 
treated with vehicle or ketamine  i.p. 30 min before the start of test. Data are median, 
n=9-10/group, the bars indicate the quartiles,  ## P<0.01  vs control group receiving  
Aqoat vehicle and vehicle, Mann-Whitney U-test, ** P<0.01 Kruskal-Wallis ANOVA 
followed by Dunn's Multiple Comparison Test. B) Male Lister-Hooded rats were 
trained to criterion in the eight-arm radial maze for 18 days to retrieve bait placed in 
four of the arms.  The location of the baits was changed before each trial. Drug 
treatments on the day of the trail were as for A.  Data are median the bras indicate 
the quartiles, n=9-10/group.  ## P<0.01 vs. control group receiving  Aqoat vehicle 
and vehicle, Mann-Whitney U-test, ** P<0.01 Kruskal-Wallis ANOVA followed by 
Dunn's Multiple Comparison Test. 
Fig. 5 Effect of S44819 on the extinction of cued fear. Male C57BL/6J mice were 
conditioned by pairing white noise with mild electric shock on day 1. The extinction of 
the freezing response to noise alone was followed over the next 4 days.   Animals 
were injected with S44819 (nanoF3, 3 mg/kg i.p.)  30 min prior to each extinction 
session (indicated by upward arrows).  Data were analysed by one-way ANOVA 
followed by Dunnett’s test for multiple comparisons.   ** P<0.01 vs. the respective 
values obtained on day 1.      
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Fig. 6 Enhancement of social interaction in rats by S44819. Pairs of male Wistar rats 
receiving the same pharmacological treatment were studied. Rats were pretreated 
with vehicle of S44819 i.p. 30 min prior to the start of the observation period with 
lasted 10 min.  A) Time spent engaged in social interactions expressed as 
percentage of total observation time. B) Active exploration expressed as percentage 
of total observation time. ** P<0.01 when compared with the respective group 
receiving  vehicle (0 mg/kg). Data were analyzed by Kruskal-Wallis ANOVA. The 
Mann-Whitney test was used for post-hoc comparisons.  Sample size was 12, but 
one pair was discarded from the chlordiazepoxide group for technical reasons. 
Therefore, the sample size was 10 in this group. 
Fig. 7 Anxiolytic-like effect of S 4819 in the fear potentiated startle model in rats (male 
Sprague-Dawley) after acute i.p. administration. Values are mean ± SEM (n=8-14 
/group). # P <0.05 Student’s two-tailed t-test between diazepam and the control 
group receiving vehicle to validate the test, * P<0.05 vs. group receiving vehicle (0 
mg/kg), one-way ANOVA followed by Dunnett's post-hoc test for the doses of 
S44819 used.  
Fig. 8 Reversal of shock induced decrease in opponent time by S44819 in young male 
Wistar rats. Treatment with vehicle of S44819 (nano F3) was given 30 min before 
the start of the social avoidance paradigm.  Values are mean ± S.E.M. (n=8-9) ##: 
p<0.01, test validation, Student’s t-test versus non-shocked control, * P<0.05 versus 
shocked control (0 mg/mkg). One-way ANOVA followed by Dunnett's post-hoc test 
for multiple comparisons. 
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Figure 6 Fear potentiated startle
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Figure 8
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Highlights: 
 
• A novel competitive inhibitor selective	for	extrasynaptic	α5-GABAA receptors	(S44819)	
was	tested	in	behavioral	paradigms.	
	
•	The	compound	was	effective	in	improving	long-term	as	well	as	short-term	(working)	
memory	in	mice	and	rats.		
	
•	It	was	effective	in	reversing	the	impairment	of	object	recognition	memory	induced	by	sub-
chronic	treatment	of	mice	with	phencyclidine.	
	
•	S44819	also	showed	significant	anxiolytic/antidepressant-like	activity	in	tests	that	have	a	
mnemonic	component.	
	
•	The	compound	is	now	in	Phase	2	clinical	trials.	
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ABSTRACT 
Previous work has shown that S44819 is a novel GABAA receptor (GABAAR) antagonist, which is 
selective for extrasynaptic GABAARs incorporating the α5 subunit (α5-GABAARs). The present 
study reports on the preclinical neuropsychopharmacological profile of S44819. Significantly, no 
sedative or pro-convulsive side effects of S44819 were found at doses up to 30 mg/kg i.p.. Object 
recognition (OR) memory in intact mice was enhanced by S44819 (0.3 mg/kg p.o.) given before 
the acquisition trial. Mice treated with phencyclidine for two weeks and tested six days after the 
cessation of treatment failed to show OR memory. This deficit was corrected by a single 
administration of S44819 (0.1, 0.3 or 1 mg/kg p.o.) prior to the acquisition trial. The amnestic effect 
of ketamine in rats tested in the eight-arm radial maze (reference and working memory versions) 
was blocked by S44819 (3 mg/kg p.o.). Extinction of cued fear was preserved during treatment 
with S44819 (3 mg/kg/diem i.p.). Administration of S44819 had no significant effect in the Vogel-
conflict test, the elevated plus maze, the forced swim, the marble-burying and the tail-suspension 
tests. In contrast, anxiolytic/antidepressant-like effects of the compound were found in paradigms 
that have mnemonic components, such as social interaction, fear-potentiated startle and social 
avoidance induced by negative life experience. In summary, S44819 enhanced intact recognition 
memory and ameliorated memory deficits induced by inhibition of NMDA receptors. 
Anxiolytic/antidepressant efficacy was limited to paradigms involving cognitive function. In 
conclusion, S44819 is a novel psychoactive pro-cognitive compound with potential as a therapeutic 
agent in dementia. 
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1. Introduction 
 
Gamma-aminobutyric acid (GABA) is a fundamentally important neurotransmitter in the CNS 
(Klausberger and Somogyi, 2008; Walker, 1983). The actions of GABA are mediated by ionotropic 
GABAA (GABAARs) and metabotropic GABAB receptors. The topographical distribution of GABAAR 
subunits in the brain indicates non-redundant functions (Pirker et al., 2000; Wisden et al., 1992). 
Indeed, in a pioneering studies analysing genetically engineered mice, the groups of Rudolph and 
Möhler and of McKernan and Whiting (reviewed by (Rudolph and Möhler, 2014)), showed that the 
diverse effects of diazepam on brain function were attributable to GABAARs incorporating specific 
α-subunits. These studies were the first to show that α5-GABAARs influence cognitive functions. 
Thus, the physiologic rationale of producing GABAA isoform selective pharmacons as therapeutic 
agents was established (Dawson et al., 2005). 
 
The chemical synthesis and biological characterization of a family of tricyclic compounds, based on 
a 2,3-benzodiazepine scaffold, that are competitive inhibitors of GABA binding at the α−β subunit 
interface, was previously reported (Etherington et al., 2017; Ling et al., 2015). For some 
compounds, orthosteric antagonism was paired with inhibition of Cl--channel gating, similar to the 
properties of the GABAAR antagonist, bicuculline (Ueno et al., 1997). However, in contrast to 
bicuculline, which is a non-selective blocker of most GABAAR isoforms, some of the novel 
compounds show considerable isoform selectivity. A potentially valuable compound in the series is 
S44819, which is a largely selective inhibitor of extrasynaptic α5-GABAARs in vitro (Etherington et 
al., 2017). The current paper reports the in vivo preclinical pharmacology of this molecule.  The 
results show enhancement of normal as well as remediation of impaired cognitive function, 
including object recognition memory, spatial working and reference memory by S44819. The 
compound also showed significant anxiolytic/antidepressant-like activity in tests that have a 
mnemonic component.  
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2. Methods 
 
2.1  Animals 
Male rats (190–270 g BW), or mice (20-30 g BW) — the strains are specified under the headings 
of the respective tests — were housed under standardized laboratory conditions (24 ± 2 ºC, 40–
60% relative humidity), on a 12-h light/dark cycle with light onset at 6:00 AM. All experimental 
protocols were approved by the Animal Care and Use Ethical Committee of Egis Pharmaceuticals 
PLC and complied with the Hungarian Law of Animal Care and Use (1998. XVIII).  
 
2.2 Compounds 
S44189 (Egis-13529), substituted 8-methyl-5-[1-benzothiophen-2-yl]-1,9-dihydro-2H-[1,3]oxazolo [4,5-
h][2,3]benzodiazepin-2-one was produced as free base at greater than 97% purity at Egis 
Pharmaceuticals PLC as previously described (Ling et al., 2012; Ling et al., 2015). The solubility of 
the compound in physiological buffers containing 0.1% DMSO (v/v) was around 50 µM. 
Furthermore, because of the poor oral bioavailability of S44819 (F < 2%) the compound had to be 
micro-formulated for preclinical studies. Two formulations of S44819 were provided by Dr Caroline 
Chemin, Technologie Servier, (Orleans, France). The first, Aqoat, was a suspension of micro-
milled S44819/Hypromellose Acetate Succinate (Shin Etsu Chemical Co, Japan)/Magnesium 
stearate (30/69.5/0.5, w/w/w) suspended in 2% (w/v) hydroxy-ethylcellulose (Molar Chemicals Ltd, 
Budapest). The second, (nanoF3) was a nano-encapsulated formulation consisting of S44819 
3.85/Lipoïd S100 (Lipoïd GmbH, Ludwigshafen, Germany) 38.5/trehalose 57.7, w/w/w). Both 
formulations were used for intra-peritoneal (i.p.) as well as oral (p.o.) administration. The 
preparations were administered on the basis of their free base active product ingredient content. 
An effort was made to minimize the exposure of the animals to the excipients.  Thus, the amount of 
excipient used depended on the highest dose of the drug administered in a given experiment — 
importantly, the dose of excipient was kept constant within a particular study. The highest dose of 
S44819 formulated with Aqoat was 30 mg/kg, thus all animals in received 0.50 mg/kg magnesium 
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stearate, 71 mg/kg hypromellose acetate succinate and 0.1 mg/kg of hydroxy-ethylcellulose. The 
dose of excipients was kept constant with reduced doses of drug. In the case of nanoF3, the 
highest dose used was 30 mg/kg of S44819, thus the animals also received 300 mg/kg Lipoïd 
S100 and 450mg/kg of trehalose. The dose of excipients was kept constant with reduced doses of 
drug. The drug administration regimes described below were optimized on the basis of preliminary 
kinetic studies in mice and rats with both formulations of S44819.  Notably, both formulations gave 
similar brain:plasma concentration ratios approximating 1:2 in male mice (see Suppl. Fig.-s 1 and 
2) and 1:4 in male rats (data not shown). 
 
2.3 Object recognition assay in mice 
Male albino NMRI mice bred in house were used. The experimental protocol was analogous to that 
described for rats (Gacsályi et al., 2013). Briefly, Day 0, familiarization: mice spent 2.5 minutes in a 
24 x 34 x 24 cm box with black plastic walls. Acquisition: on the next day mice were allowed to 
explore freely two identical objects placed symmetrically at 4-4 cm from the shorter sides of the 
box. The animals were removed from the box when exploration times of both objects reached 10 
s/object during a maximum 5 min period. Retention: 24 h later the animals were allowed to explore  
a novel object and an identical copy of the familiar object — the exploration time for both objects 
was recorded for 4 min. Treatment with Aqoat-formulated S44819 (0.03, 0.1, 0.3 mg/kg), or vehicle 
was performed p.o. 120 min before the start of the acquisition trial. Data were analysed by one-
way analysis of variance followed by Dunnett's multiple comparison test. 
 
In another series of experiments NMRI mice were subjected to sub-chronic treatment with vehicle 
(0.9% w/v NaCl), or phencyclidine (PCP, supplied by Tocris, U.K.): 3 mg/kg i.p. twice a day for a 
total of ten days (2x 5 days with a two-day break). Six days after the last PCP treatment, S44819 
at 0.1, 0.3 and 1 mg/kg was administered p.o. 120 min before the start of the acquisition trial. The 
study protocol was exactly the same as above, except that the retention trial took place 15 min 
after the start of the acquisition period. Animals were returned to their home cage between the 
acquisition and retention trials. Data were analysed by Student’s t-test to validate the effect of PCP 
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(control vs. vehicle i.e. 0 mg/kg S44819-group) and one-way ANOVA followed by Dunnett's 
multiple comparison test (vehicle vs. S44819-treated groups) to assess the effect of S44819.  
 
 
2.4 Working memory in the eight-arm radial maze in rats 
 
Male Lister-Hooded rats 185-228 g body weight (Harlan Laboratories, The Netherlands) were 
trained and tested in an eight-arm-maze-based spatial working memory task in a dimly lit special 
room where geometric shapes were placed on the walls as visual cues. (Gacsályi et al., 2013). 
The maze was constructed from Perspex. It consisted of a central octagonal platform (diameter: 28 
cm) and 8 radial direction arms (width: 9.5 cm, length: 70 cm, wall height: 12 cm). The central part 
and the arms had removable Perspex covers. Bait-food (5 mm diameter pellets made from a 
mixture (1:1, w/w) of ground tea-biscuits (Győri Otthon Keksz, Tesco stores, Budapest) and instant 
cocoa powder (Nesquik, Nestlé, Tesco stores)) was placed in a cavity at end of the arms. It was 
verified in previous independent studies, that the animals used the visual cues to find the bait. 
Young adult male Lister-Hooded rats were handled daily by the experimenter and were relatively 
food-deprived receiving approximately 8-10 g standard rodent food/day/animal per day. Training 
continued for 13 days (suspended on weekends). Rats were placed onto the central platform of the 
maze with all 8 arms baited. Rats were allowed to eat the bait from all 8 arms. If the rat did not eat 
all of the baits within 20 min it was removed from the maze. The following parameters were 
recorded. Repetition error (RE) is visiting the same arm more than once, Initial correct responses 
(ICR) is number of correct entries until first error. Animals included in the study had RE values <3 
or ICR ≥7. On the last day of the experiment (after 13 days training) animals were given vehicle, or 
Aqoat-formulated S44819 p.o. (0.3, 1 and 3 mg/kg) and ketamine 10 mg/kg i.p., at 120 and 30 min 
before the start of the trial, respectively. A single trial lasted a maximum of 5 min. The numbers of 
RE-s were analyzed by non-parametric Mann-Whitney test (intact control vs. ketamine control 
group) and Kruskal-Wallis test, followed by Dunn’s multiple comparison test (ketamine control 
group vs. ketamine + different S44819 doses) 
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2.5 Reference memory in the eight-arm radial maze in rats  
Reference memory was studied in male Lister-Hooded rats 230-310 g body weight with the same 
equipment and protocol as working memory (described above) with the following modifications. 
Only four arms out of eight were baited in the training sessions. Baiting was arranged in ten 
different configurations to the eight arms, a given animal was trained on the same configuration of 
arms throughout the entire experiment. Rats were allowed to eat the bait from all 4 arms. If the rat 
did not consume all the baits within 20 min it was removed from the maze. Training runs were 
performed once a day for 18 days (excluding weekends). On the last day of the experiment (after 
18 days training) the animals were given vehicle, or Aqoat-formulated S44819 (0.3, 1 and 3 mg/kg, 
p.o.) and ketamine 10 mg/kg i.p., at 120 and 30 min before the start of the trial, respectively. The 
numbers of errors, i.e. the number of entries into arms that had never been baited and the number 
of the missed baited arms within the 5 min of testing, were recorded. Inclusion criteria: 1) the rat 
performs perfectly at least once in the last 3 learning days within 5 min, or 2) the rat has less than 
3 errors, or makes a mistake after the 3 correct entries in the last learning day in 5 or less minutes. 
The numbers of errors were analyzed by the Mann-Whitney U-test and the Kruskal-Wallis ANOVA 
followed by Dunn's multiple comparison test. 
 
2.6 Extinction of cued fear 
 
The subjects were male young adult C57BL/6J mice (20-25 g BW, Charles River, Germany). 
Apparatus: TSE Fear Conditioning System (TSE System GmbH, Bad Homburg, Germany), four 
animals were tested simultaneously. The protocol is summarized in Fig.5. Fear conditioning (Day 
1): Mice were placed into the test chambers (21.5 cm x 21.5 cm x 35 cm) and after 3 min 
habituation were given the first of 3 noise/foot-shock pairings. The 0.7 mA, 2 s electric shock was 
delivered during the last 2 s of the 30 s exposure to white noise (85 dB). The average inter-trial 
interval was 2 min. Extinction procedure (Days 2 - 5): Twenty four h after the last trial, S44819 (3 
mg/kg, nanoF3 formulated), or vehicle was administered i.p. each day 30 min before the start of 
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the extinction session. Mice were then placed into the same chamber where they received the 
conditioning and after 3 min habituation, were exposed to 4 x 30 s of white noise (85 dB) – inter-
trial intervals were 60 s. The number of freezing reactions was recorded. The reaction was 
considered freezing if the mouse was immobile for a minimum 2 s. Freezing was scored by 
dividing the 30 s noise stimulus into 5 s bins. If the animal froze in all 6 bins it received a score of 
6.  Four noise stimuli were given in total and the percentage of bins in which freezing was evident 
was calculated for each animal. Data were analyzed by one-way ANOVA followed by Dunnett’s 
test for multiple comparisons. 
 
2.7 Fear potentiated startle response test in rats 
Male Sprague-Dawley rats bred in house were used. The fear potentiated startle procedure (Davis 
et al., 1993; Walker and Davis, 1997) also see Suppl. Fig. 11, consisted of learning, pre-test and 
test periods. In the learning period over two consecutive days, male Sprague-Dawley rats were 
placed into the test chambers and 5 min later given the first of 10 light/foot-shock pairings. The 1 
mA, 0.5 s shock was delivered during the last 0.5 s of the 3.7 s light pulse. The average inter-trial 
interval (ITI) was 3 min. Background noise: 55 dB. Twenty-four h after the learning period, rats 
were returned to the test chambers for the pre-test phase. Five min later 10 x 95 dB noise bursts 
(ITI: 20-40 s) were presented (habituation). After 30 s, 3 noise alone stimuli (95 dB) and 3 noise + 
light stimuli were presented. On the test day (24 h after the completion of pre-test) the rats were 
returned to the test chambers and 5 min later were presented with the same initial habituation 
noise. 30 s later 10-10 noise alone (95 dB) and noise + light stimuli in random order were 
presented to the animal. The calculated parameter is the difference in the magnitude of startle 
responses between “light + noise” and “noise alone” trials. (Difference = magnitude of startle 
response at “light-noise” trials – magnitude of startle response at “noise alone” trials). Acute 
treatment with vehicle, or S44819 (nanoF3, 1, 3 and 10 mg/kg i.p.), was on the test day 30 min 
before the trial. The positive control diazepam was administered acutely at 3 mg/kg, i.p. 30 min 
before the test. Data were analyzed by one-way ANOVA followed by Dunnett’s test for multiple 
comparisons.  
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2.8 Social interaction in rats 
 
The study was carried out on 60 male Wistar rats (Charles River Laboratories, Hungary) 190-210 
g body weight. After their arrival in the animal facility, rats were housed in groups of four in cages 
measuring 45 x 30 x 20 cm. One week of habituation to local conditions was allowed. Rats were 
familiarized with the test apparatus by being placed individually into the test arena for 10 min on 
the last two days of the habituation. Rats were weighed on the last habituation day. Experiments 
were performed in two sessions on two consecutive days. Treatments were balanced over 
sessions. Pharmacological treatments were performed one day after the last individual exposure 
to the test arena, during the first half of the dark phase. The effects of vehicle and S44819 
(nanoF3, 1 ,3 10 mg/kg i.p.) were compared together with 10 mg/kg chlordiazepoxide (CDP) as 
reference. Sample size was 12, but one pair was discarded from the chlordiazepoxide group for 
technical reasons. Therefore, the sample size was 10 in this group. Pairs of rats were placed in 
the test arena (60 x 50 x 40 cm) 30 min after drug treatment and observed for 10 min. The 
members of the pairs were unfamiliar to each other and received the same pharmacological 
treatment. Behavior was video-recorded through the transparent front wall of the test cage and 
later analyzed by means of a computer-based event recorder by an experimenter blind to the 
drug treatment regimen. The social interaction test arena was a dark grey plastic box of 40 x 60 x 
50 cm with wood shaving bedding. Boxes were lit by white light. The front wall of the box was of 
transparent plastic. Six boxes were used in parallel. Fresh bedding was used for each pair of rats. 
The duration and the frequency of social interactions (sniffing partner; anogenital sniffing; 
following; allogrooming) and total amount time spent moving around the arena (exploration) were 
recorded. An increase in social interactions is consistent with an anxiolytic action. Increased 
resting and decreased exploration were considered signs of sedative or locomotor suppressive 
effects. The parameter analysed was the amount of time engaged in social interaction expressed 
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as a percentage of the total exploration time. Data were analyzed by Kruskal-Wallis ANOVA. The 
Mann-Whitney test was used for post-hoc comparisons.  
 
 
2.9 Social avoidance induced by electric shock 
The test was carried out in young male Wistar rats (7-9 weeks old, 250-350 g body weight) as 
previously reported (Leveleki et al., 2006; Sziray et al., 2007). Briefly, inescapable electric shocks 
(24 shocks, 3 mA, 1 s duration, 29 s interval) were delivered 1 day before the social avoidance test 
via the grid floor. Twenty-four h later, the social avoidance testing was performed in a different box 
from the one in which the foot shocks were delivered. Animals were injected i.p. with S44819 
(nanoF3 0.3 and 1 mg/kg), or vehicle 30 min before the test. The subject was placed in a cage (16 
x 52 cm) for a 3 min habituation period upon which a sliding door leading to a larger cage (40.5 x 
41 cm) was opened. The larger cage was divided into two equal (40.5 cm x 20.5 cm) 
compartments by a transparent, perforated plastic wall running down the middle. The distant 
compartment contained a large, unfamiliar male Wistar rat (>11 weeks old, >400 g body weight), 
as the opponent. The opponent was un-shocked. The subject was allowed to explore the resulting 
space for 5 min. The test apparatus did not permit physical contact between the experimental and 
stimulus animals. The duration of visits made to the middle compartment (opponent time) was 
recorded and expressed as percentage of the total time of exploration (% opponent time). Data 
were analyzed by one-way ANOVA followed by Dunnett’s test for multiple comparisons. 
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3. Results 
 
Analysis of spontaneous locomotor activity (see Supplementary methods) indicated that nano-
formulated S44819 had no sedative, or anxiogenic actions at doses up to 30 mg/kg i.p. (Fig. 1A). 
Further tests of anxiety were in agreement with this conclusion (Suppl. Figs. 4-7). Moreover, there 
were no signs of muscle weakness/relaxation in the inclined screen test at doses up to 100 mg/kg 
in marked contrast with Baclofen and Diazepam at 10ml/kg, i.p. both of which had a significant 
effect on muscle strength (Suppl. Fig. 3).  Non-selective inhibition of GABAA receptors results in 
the lowering of the convulsion threshold (Stephens and Turski, 1993). This was indeed the case 
upon chronic administration of pentylenetetrazole (40 mg/kg i.p, see Supplementary methods): by 
day 18, 60 % of the animals displayed clonic seizures (Fig.1B). In contrast, there were no signs of 
seizures in the group given the same dosage of S44819 (Fig.1B). 
 
3.1 Novel object preference in mice 
 In intact male mice, acute administration of Aqoat formulated S44819 at 0.3 mg/kg p.o., given 120 
min prior to the acquisition trial, significantly increased the time spent investigating the novel object 
over the familiar object 24 h after acquisition (Fig. 2). Note that in this study the time for object 
exploration and the inter-trial interval were adjusted so that the control animals had no significant 
retention of the object explored during the acquisition trial. Other dosage regimes of the drug were 
not tested.  
The effect of S44819 on PCP-induced memory deficit was also examined. As reported previously 
by others (Grayson et al., 2007; Redrobe et al., 2010), mice subjected to sub-chronic treatment 
with PCP failed to show significant short-term object recognition memory (Fig. 3). Acute 
administration of S44819 at 0.1, 0.3 and 1 mg/kg, p.o. 120 min before the acquisition trial fully 
restored recognition memory in a dose-dependent manner (Fig. 3). 
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3.2 Remediation of ketamine-induced impairments of working and reference memory in the eight-
arm radial maze in rats 
Male rats were tested in the eight-arm maze in order to assess the effect of S44819 (0.3, 1 and 3 
mg/kg, p.o.) in cognitive disruption induced by ketamine. Indeed, acute administration of ketamine 
(10 mg/kg) produced significant deterioration of working, as well as reference memory in the eight-
arm radial maze (Fig. 4A & B). Acute administration of S44819 (Aqoat, 0.3 - 3 mg/kg p.o. 120 min 
before the trial) improved performance in both paradigms with 3 mg/kg being close to maximally 
effective.   
 
3.3 Extinction of cued fear in mice 
It has been reported that synaptic plasticity in the form of LTD, in addition to LTP are important for 
the extinction of cued fear (Myers and Davis, 2006; Nabavi et al., 2014). As S44819 facilitated 
hippocampal CA1 neuron LTP (Etherington et al., 2017) and as α5-GABAARs may facilitate LTD 
(Martin et al., 2010), it was of interest to test whether or not S44819 had any effect on the 
extinction of cued fear by causing an imbalance of neuronal plasticity favouring LTP. The effect of 
S44819 on the extinction of cued fear was tested at 3 mg/kg daily, i.p. in mice (Fig. 5). Fear 
extinction was observed in vehicle as well as the S44819 treated groups. While in the control 
group the decrement in freezing behavior was significant only on day 5, in the S44819 treated 
groups there was a significant reduction on days 4 and 5. Taken together, S44819 (3mg/kg daily) 
had no deleterious effects on the extinction process, if anything, a small degree of enhancement of 
fear extinction was apparent on day 4.   
 
3.4 Fear potentiated startle in rats 
The potentiation of acoustic startle reflex by experimentally induced fear has been used as a 
preclinical surrogate of general anxiety disorder (Davis et al., 1993). As recent reports have 
suggested that α5-GABARs could mediate the anxiolytic effects of endogenous GABA (Behlke et 
al., 2016; Botta et al., 2015), an antagonist of these receptors, such as S44819 may prove to be 
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anxiogenic.  Importantly, treatment with S44819 at 1 and 3 mg/kg produced a marked reduction of 
the enhancement of the startle response by the conditional light-pulse stimulus (Fig. 6), whereas 
no significant effect was observed at 10 mg/kg (Fig. 6). The compound (up to 10 mg/kg) had no 
effect of the basal startle reflex (data not shown). The reference anxiolytic compound diazepam 
(3mg/kg, i.p.) also significantly decreased the fear potentiated startle response of rats. 
 
3.5 Social avoidance upon (electric shock) in rats 
This test is a long-term model of social anxiety induced by a negative experience, which is 
sensitive to anxiolytic and anti-depressant drugs (Leveleki et al., 2006). A train of electric foot-
shocks produced a significant level of social avoidance 24 h later (Fig. 7). Administration of 
S44819 (nanoF3, 0.3-1 mg/kg i.p.) 30 min before the social avoidance trial reversed the effect of 
prior electric shock (Fig. 7).  
 
3.6 Social interaction in rats 
The social interaction paradigm is used to evaluate the level of spontaneous anxiety in laboratory 
rodents. In male Wistar rats, the amount of time engaged in social interactions was dose-
dependently enhanced by S44819 (1-10 mg/kp i.p.) (Fig. 8A). The lowest effective dose was 1 
mg/kg i.p. (Fig. 8A). Importantly, no effect on exploration time was apparent for S44819 at doses 
up to 10 mg/kg (Fig. 8B). The effect of S44819 was equivalent to that produced by CDP (10 mg/kg 
i.p.), but note, that in contrast to S44819, CDP at this dose decreased the exploration time, i.e. had 
a sedative effect.  
 
4. Discussion and conclusions 
The data presented here demonstrate that S44819 can enhance normal learning and memory as 
well as ameliorate the impairment of these processes induced by acute, or sub-chronic inhibition of 
NMDA receptors by ketamine and PCP, respectively.  Given the effects of S44819 to improve 
learning and memory, it was important to analyze its efficacy in tests of anxiety, fear and 
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depression. The results of the latter group of studies demonstrated that the anxiolytic efficacy of 
S44819 was manifested in paradigms that engaged a cognitive component in the behavior. 
 
An extensive body of evidence has accumulated showing that a reduction of α5-GABAAR function 
by pharmacological or genetic methods, improves cognitive performance in a variety of paradigms 
(Atack, 2011; Rudolph and Möhler, 2014). The pharmacons previously studied in this respect were 
all benzodiazepine site NAMs (Atack, 2011; Ballard et al., 2009; Chambers et al., 2003). In 
principle, S44819, a novel competitive blocker of α5-GABAARs (Etherington et al., 2017) offers a 
potentially important advantage over α5-GABAAR NAMs. Due to the relatively low affinity for its 
target, S44819 is likely to block the activation of extrasynaptic α5-GABAARs exposed to maximally 
1 µM of GABA, but to be largely ineffective against the high concentrations of GABA that occur in 
the synaptic cleft (Etherington et al., 2017; Ling et al., 2015). In contrast, α5-GABAAR NAMs 
reduce the activity of synaptic (Salesse et al., 2011) as well as extrasynaptic α5-GABAARs 
(Caraiscos et al., 2004; Glykys et al., 2008; Martin et al., 2010). Importantly, as expected of an α5-
GABAAR selective GABAA antagonist (Dawson et al., 2006) and in contrast to non-selective 
inhibitors of GABAA receptors, S44819 had no sedative or pro-convulsive effects. 
 
The current study demonstrated the improvement of cognitive performance by S44819 in a variety 
of experimental paradigms. Long-term object recognition memory could be enhanced by S44819 in 
intact mice (present study) as well as rats (Etherington et al., 2017). Furthermore, similar to the 
effect of an α5-GABAA NAM in rats (Redrobe et al., 2012), the dramatic impairment of object 
recognition memory induced by subchronic PCP treatment of mice was reversed by acute 
treatment with S44819. Acute treatment with S44819 also improved declarative and working 
spatial memory disrupted by ketamine. Previously, it was also found to be effective against 
impairments of working memory induced by scopolamine (Etherington et al., 2017). Collectively, 
these results militate for actions of S44819 in the hippocampal gyrus and the neocortex. Indeed, 
previous work has shown that S44819 reduces tonic inhibition and potentiates LTP induced by a 
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theta-burst stimulation protocol in mouse CA1 pyramidal neurons (Etherington et al., 2017) and 
enhances the excitability of neurons in the M1 region of the human motor cortex (Darmani et al., 
2016). 
 
The outcomes of preclinical assays of cognitive performance may be markedly influenced by 
changes in the levels of learned and innate fear, or anxiety. Thus, we have examined the effect of 
S44819 in standard assays of anxiety and depression (see Suppl. Fig.-s 3-9). These studies 
revealed that S44819 was essentially without effect in these assays, except for the light-dark box 
paradigm where it had a significant anxiolytic effect at 30 mg/kg (Suppl. Fig. 5). In less standard 
assays, such as fear-potentiated startle, social interaction, and social avoidance induced by 
traumatic stress, the compound proved to be effective. Both fear-potentiated startle (Davis et al., 
1993) and social interaction (File and Seth, 2003) are sensitive to the acute administration of 
anxiolytics such as diazepam and buspirone. However, in considering the interaction with the 
GABAAR, S44819 is distinct from 1,4-benzodiazepines, being a competitive antagonist of the 
GABA recognition site (Etherington et al., 2017). Moreover, it shows no appreciable effect on any 
of the receptors known to interact with buspirone. Classic antidepressant compounds such as 
fluoxetine are anxiogenic when given acutely in the fear-potentiated startle, as well as the social 
interaction paradigms (Davis et al., 1993; File and Seth, 2003). It is clear that social-interaction 
involves early learning and memory experience that is recalled during the test (File and Seth, 
2003), and may be facilitated by S44819. Fear-potentiated startle has an element of conditioned 
fear and anatomically involves the central amygdala (Davis et al., 1993; Walker and Davis, 1997). 
The facilitation by S44819 of cognitive surveillance of the conditioned stimulus-association could 
contribute to the reduction of startle amplitude. Furthermore, recent work has highlighted the 
involvement of tonic, α5-GABAAR mediated inhibition in regulating the activity of PKCδ expressing 
neurons in the central amygdala (Botta et al., 2015), which is a key brain site for fear conditioning 
(Ciocchi et al., 2010). Thus it cannot be excluded, that in addition to effects on cognitive 
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performance, neurons of the central amygdala are also substrates of the action of S44819 in the 
fear-potentiated startle paradigm. 
 
Social avoidance produced by the single traumatic stress model described here, is diminished by 
antidepressants such as fluoxetine (Leveleki et al., 2006; Sziray et al., 2007). A rapid anti-
depressant-like action of α5-GABAA NAMs to reduce social avoidance in animals subjected to 
chronic stress paradigms has been recently reported (Fischell et al., 2015). The efficacy of these 
compounds has been ascribed to the restoration of reduced AMPA receptor mediated synaptic 
transmission in the temporoammonic-hippocampal CA1 pathway (Fischell et al., 2015). Similar to 
other α5-GABAAR inhibitors, S44819 enhanced theta-burst long-term potentiation in the CA1 area 
(Etherington et al., 2017). Thus, the parsimonious explanation for the efficacy of S44819 in social 
avoidance induced by traumatic stress is the potential for a dual mechanism of action at the level 
of associative memory as well as the affective filters in the amygdala resulting in the improvement 
of the behavioural response to stress. However, recent data (Botta et al., 2015) indicate, that by 
altering the excitability of neurons expressing α5-GABAAR in the central amygdala, S44819 could 
also directly influence affective components of behaviour warranting further studies in this area. 
   
In summary, we have demonstrated the enhancement as well as remediation of learning and 
memory by S44819 in several cognitive domains. The compound did not produce the side effects 
such as sedation, muscle weakness or pro-convulsive symptoms, which are characteristic of non-
selective enhancers of GABA action. We also found that the S44819 has efficacy in preclinical 
assays of anxiety and traumatic stress that all have mnemonic components, i.e. the anxiolytic/anti-
depressant-like efficacy of S44819 could be secondary to the facilitation of cognitive processes. 
Notably, S44819 has been shown to alter the EEG response to transcranial magnetic stimulation in 
humans (Darmani et al., 2016) and is now in Phase 2 clinical trials 
(https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001005-16/HU). 
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LEGENDS TO THE FIGURES 
Fig. 1 A) No appreciable effect of S44819 (nanoF3, up to at 30 mg/kg i.p) on 
spontaneous motor activity. Data are mean ± S.E.M. n=8/group. B) No apparent 
kindling effect of 40 mg/kg i.p. S44819 (nanoF3) in male NMRI mice after up to 19 
days of treatment.  Note prominent epileptogenic kindling by pentylenetetrazole 
(see Supplement for methods).  n=10/group.  
Fig. 2 Object recognition memory is enhanced by S44819 in intact NMRI mice. The test trial 
with the new object was carried out 24 h after the acquisition trial with two identical 
objects.  S44819 (Aqoat) was given p.o. 120  min before the acquisition trial.  The 
discrimination index (DI) is shown where N is the time spent inspecting the new 
object, F is the time spent exploring  the familiar object during the test trial.  Data 
are mean ± S.E.M. n=10/group.  ** P<0.01  one-way ANOVA  followed by Dunnett’s 
test vs. vehicle (0 mg/kg) group.  
Fig. 3 Reversal by S44819 of the impairment of object recognition memory induced by sub-
chronic treatment with PCP.   NMRI mice were treated with saline or PCP 3 mg/kg 
twice daily i.p. for 2 x 5 days with a two-day pause between the two courses of 
treatment.  Ten days after the last treatment with PCP object recognition memory 
was tested by examining novel object preference in the two-object version of the 
test. The test trial took place 15 min after the acquisition trial.  Treatment with 
S44819 or vehicle (Aqoat, p.o.) was 120  min before the onset of acquisition.  Data 
are mean ± S.E.M. n=10/group. ### P<0.001 Student’s t-test vs Control (CTRL) 
group subchronically treated with saline and acutely receiving vehicle. ** P<0.01 
***P<0.001 one-way ANOVA  followed by Dunnett’s test vs vehicle (0 mg/kg) group 
with had received PCP.  
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Fig. 4 The acute disruptive effect of 10 mg/kg ketamine on spatial reference (A)  and 
working (B) memory is opposed by S44819.  A) Male Lister-Hooded rats were 
trained to criterion  in the eight-arm radial maze for 13 days to retrieve bait placed in 
four of the arms.  On the day of the test trial the animals received vehicle or  S44819 
(Aqoat,  0.3, 1, 3 mg/kg p.o. )  120  min prior to the start of the test. They were 
treated with vehicle or ketamine  i.p. 30 min before the start of test. Data are median, 
n=9-10/group, the bars indicate the quartiles,  ## P<0.01  vs control group receiving  
Aqoat vehicle and vehicle, Mann-Whitney U-test, ** P<0.01 Kruskal-Wallis ANOVA 
followed by Dunn's Multiple Comparison Test. B) Male Lister-Hooded rats were 
trained to criterion in the eight-arm radial maze for 18 days to retrieve bait placed in 
four of the arms.  The location of the baits was changed before each trial. Drug 
treatments on the day of the trail were as for A.  Data are median the bras indicate 
the quartiles, n=9-10/group.  ## P<0.01 vs. control group receiving  Aqoat vehicle 
and vehicle, Mann-Whitney U-test, ** P<0.01 Kruskal-Wallis ANOVA followed by 
Dunn's Multiple Comparison Test. 
Fig. 5 Effect of S44819 on the extinction of cued fear. Male C57BL/6J mice were 
conditioned by pairing white noise with mild electric shock on day 1. The extinction of 
the freezing response to noise alone was followed over the next 4 days.   Animals 
were injected with S44819 (nanoF3, 3 mg/kg i.p.)  30 min prior to each extinction 
session (indicated by upward arrows).  Data were analysed by one-way ANOVA 
followed by Dunnett’s test for multiple comparisons.   ** P<0.01 vs. the respective 
values obtained on day 1.      
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Fig. 6 Enhancement of social interaction in rats by S44819. Pairs of male Wistar rats 
receiving the same pharmacological treatment were studied. Rats were pretreated 
with vehicle of S44819 i.p. 30 min prior to the start of the observation period with 
lasted 10 min.  A) Time spent engaged in social interactions expressed as 
percentage of total observation time. B) Active exploration expressed as percentage 
of total observation time. ** P<0.01 when compared with the respective group 
receiving  vehicle (0 mg/kg). Data were analyzed by Kruskal-Wallis ANOVA. The 
Mann-Whitney test was used for post-hoc comparisons.  Sample size was 12, but 
one pair was discarded from the chlordiazepoxide group for technical reasons. 
Therefore, the sample size was 10 in this group. 
Fig. 7 Anxiolytic-like effect of S 4819 in the fear potentiated startle model in rats (male 
Sprague-Dawley) after acute i.p. administration. Values are mean ± SEM (n=8-14 
/group). # P <0.05 Student’s two-tailed t-test between diazepam and the control 
group receiving vehicle to validate the test, * P<0.05 vs. group receiving vehicle (0 
mg/kg), one-way ANOVA followed by Dunnett's post-hoc test for the doses of 
S44819 used.  
Fig. 8 Reversal of shock induced decrease in opponent time by S44819 in young male 
Wistar rats. Treatment with vehicle of S44819 (nano F3) was given 30 min before 
the start of the social avoidance paradigm.  Values are mean ± S.E.M. (n=8-9) ##: 
p<0.01, test validation, Student’s t-test versus non-shocked control, * P<0.05 versus 
shocked control (0 mg/mkg). One-way ANOVA followed by Dunnett's post-hoc test 
for multiple comparisons. 
 
  
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Figure 1
Safety pharmacology in mice
S44819
PTZ
0 3 10 300
200
400
600
Number of beam iterruptions
S44819  [mg/kg i.p.]
n=8/group
5 10 15
0
20
40
60
80
Time [day]
Number of mice (%)
n=10/group
PTZ
S 44819
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Figure 2 Object recognition mice
0 0.03 0.1 0.3
0.0
0.1
0.2
0.3 **
S 44819  [mg/kg p.o.]
DI (N-F)/(N+F)
S
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Figure 3
CTRL 0 0.1 0.3 1
-0.1
0.0
0.1
0.2
0.3
0.4
S 44819 [mg/kg p.o.] 
###
**
***
***
DI (N-F/N+F)
S4 819
Object recognition mice PCP treated
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Figure 4
CTRL 0 0.3 1 3
0
1
2
3
4
##
S 44819  [ mg/kg p.o.]
**
[counts]
Total error 
CTRL 0 0.3 1 3
0
1
2
3
4
5 ##
**
[counts]
S 44819  [mg/kg p.o.]
Total error 
A. B.
44819 S4 819
Radial maze ketamine
Number of errors Number of errors
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Figure 5
3 x pairing (30 sec 
noise + 2 sec 
footshock)
24h 24h 24h24hDay1 Day2 Day4 Day5Day3
4 x 30 sec 
noise 
4 x 30 sec 
noise 
4 x 30 sec 
noise 
4 x 30 sec 
noise 
Fear extinctionFear conditioning
2 3 4  50
20
40
60
80
Time [d]
freezing [%]
**
**
**
Vehicle
S44819
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Figure 6 Fear potentiated startle
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Highlights: 
 
• A novel competitive inhibitor selective	for	extrasynaptic	α5-GABAA receptors	(S44819)	
was	tested	in	behavioral	paradigms.	
	
•	The	compound	was	effective	in	improving	long-term	as	well	as	short-term	(working)	
memory	in	mice	and	rats.		
	
•	It	was	effective	in	reversing	the	impairment	of	object	recognition	memory	induced	by	sub-
chronic	treatment	of	mice	with	phencyclidine.	
	
•	S44819	also	showed	significant	anxiolytic/antidepressant-like	activity	in	tests	that	have	a	
mnemonic	component.	
	
•	The	compound	is	now	in	Phase	2	clinical	trials.	
	
	
Behavioural pharmacology of S 44819: enhancement and remediation of cognitive 
performance in preclinical models. 
István Gacsályi, Krisztina Móricz, Gábor Gigler, János Wellmann, Katalin Nagy, István 
Ling, József Barkóczy, József Haller, Jeremy J. Lambert, Gábor Szénási, Michael Spedding, 
Ferenc A. Antoni. 
Supplementary information 
Materials and Methods 
Animals 
In experiments male NMRI or C57BL/6J mice (20-30 g) and Male SPRD (Sprague Dawley) 
rats (270-340 g) were used (Charles River Germany., Egis Pharmaceuticals PLC Hungary). 
All animals were housed under standard laboratory conditions (24 ± 2 ºC, 40-60 % relative 
humidity). Animals were kept on a 12-hour light/dark cycle with light onset at 6:00 AM with 
access to food and water ad libitum. 
Spontaneous motor activity test in mice (Fig 1A main text) 
The experiments were performed according to the method of Borsy et al. (Borsy et al., 1960)  
in a 10 channel Dews system apparatus, in separate groups of male NMRI mice. The 
animals were treated intraperitoneally (10 ml/kg) with an acute administration of the vehicle 
(vehicle group) or three doses of S 44819 (nanoF3, 3, 10 and 30 mg/kg). Sixty min after 
treatment the mice were placed into the apparatus. Dews system apparatus (10 automated 
boxes: 44 x 8 x 10 cm) was used in these experiments. The movement of animals was 
measured with 3 parallel infrared beam interruptions. The number of infrared beam 
interruptions/channel was recorded for 30 min. 
Kindling by chronic administration of drugs (Fig 1B main text) 
Kindling is a process by which repeated neuronal activation leads to a long lasting increase 
in the efficiency of transmission. The resulting hyperexcitability allows a previously ineffective 
or subthreshold stimulus to provoke seizure activity.  Male NMRI mice were used (Charles 
River Germany., Egis Pharmaceuticals PLC Hungary). The animals were treated with 40 
mg/kg i.p. of nano F3 S44819 or pentylenetetrazole once daily for 19 consecutive days. On 
each day, the mice were placed into a transparent colourless glass cylindrical pot (diameter 
10 cm, height 12 cm) immediately after drug administration and observed for the next 45 min. 
During the observation period, the behaviour of the animals (e.g. hypolocomotion, Straub tail, 
slit eyes and flattened ears) was recorded in addition to the incidence of myoclonic jerks and 
generalized seizures (characterized by clonic or tonic contraction of the limbs, including loss 
of righting reflex, i.e., the mice fell onto their side or back). After the 45-min observation 
period, mice were returned to their home cage. The treatment regime with pentylenetetrazole 
was previously published (Dawson et al., 2006; Stephens and Turski, 1993), while S 44819 
was administered at 40 mg/kg because its biological effects appeared at much lower doses. 
Plasma and brain levels of S44819 in C57bl/6 mice (Suppl. Fig 1 and 2) 
Adult male C57Bl/6J Harlan (Harlan (Envigo) Laboratories, Horst, The Netherlands) or  NMRI 
(Animal House, Egis Pharmaceutical PLC) BW 20-30 g were studied in the pharmacokinetic 
experiments. Animals were housed 6 per cage in humidity- (60±10 %) and temperature-
controlled (23±1 oC) rooms with a 12 h light/dark cycle. Food and water were provided ad 
libitum. All dosing suspensions (0.1, 0.3, 1.0 , 3.0 mg/kg) were freshly prepared on the day of 
testing, and were administered to mice in a volume of 20 ml/kg for per os (p.o.). Mice were 
deeply anesthetized with diethyl-ether (Thomasker Finomvegyszer Kft., Budapest, Hungary) 
and blood samples (0.4-0.7 ml) were taken from the vena cava posterior into Lithium-Heparin 
tubes (SARSTEDT 1.3ml LH).  The subsequent analytical procedures were identical for rat 
and mouse samples except for appropriate volume adjustments.  
Sample preparation 
Brains were homogenized with motor driven glass-Teflon homogenizers in distilled water 
(1:3=w:v). Acetonitrile (HLPC grade, Merck Kft., Budapest, Hungary) (200 µl) was added to 
50 µl of brain homogenate or plasma and the mixture was agitated on an IKA Vibrax-VXR 
platform shaker for 30 min at 1500 r.p.m. at RT, followed by centrifugation for 15 min at 
15,000 r.p.m, at RT in an Eppendorf microfuge. One hundred µl of the supernatant were 
carefully removed and vortex-mixed with 100 µl distilled water.  Ten µl of the mixture was 
used for LC-MS/MS measurement. Two parallel aliquots of each brain or plasma sample 
were assayed.  
HPLC-MS/MS 
Drug levels were determined by HPLC-MS/MS (PAL System, CTC Analytics AG.; HP Series 
1200, Agilent and Thermo TSQ Quantum Ultra, Thermo Scientific, supplied by UNICAM, 
Hungary Ltd.). Analysis was in Focus Mode on a Thermo TurboFlow CycloneP column (50 x 
0.5 mm) coupled to a Thermo Hypersil GOLD analytical column (50x3 mm, 5 µm). The 
loading pump used mobile phases of 10 mM Ammonium acetate (Merck Ltd., Budapest, 
Hungary) buffer (pH 8.8) [D], distilled water [C] and Acetonitrile (AcCN) (Merck Ltd., 
Budapest, Hungary) with 0.1 % trifluoro-acetic acid (TFA) (UvaSol, Merck Kft. Budapest, 
Hungary) [B]. The eluting pump used mobile phases of 10 mM Ammonium formate 
(MicroSelect, Fluka Chemie Ag.) buffer with 5 % AcCN (Merck Ltd., Budapest, Hungary) and 
0.1 % TFA [A] and AcCN with 0.1 % TFA [B]. The LC separation protocol is shown in Table 
1. Detector: MS/MS detection was via positive electrospray and MRM mode of scanning. 
Sample tray temperature: 23 °C; injection volume: 10 µl and the total run time was 7.10 min. 
 
 
 
TABLE 1 
Step Start Sec Flow Grad %A %B %C %D Tee Loop Flow Grad %A %B 
1 0:00 30 1.5 Step -  - 100 ---- out 0.65 Step 100  
2 0:30 60 0.2 Step -  - 100 T in 0.55 Step 100  
3 1:30 30 1.5 Step   100   out 0.40 Step 100  
4 2:00 30 1.5 Step - 100 -  ---- out 0.40 Ramp 35 65 
5 2:30 60 1.5 Step - 100 -  ---- out 0.40 Ramp 5 95 
6 3:30 30 1.5 Step - 100 -  ---- in 0.40 Step  100 
7 4:00 40 1.5 Step - 100 -  ---- in 0.40 Step  100 
8 4:40 30 1.5 Step   100   out 0.40 Step  100 
9 5:10 60 1.5 Step -  - 100 ---- out 0.40 Step  100 
10 6:10 60 1.5 Step -  - 100 ---- out 0.65 Step 100  
 
Two parallel runs of calibration samples were also prepared (known concentrations of the 
drugs spiked into blank plasma and homogenized brain, the whole sample preparation 
process was performed). Blank plasma and brain samples were injected before the 
calibrations for the system suitability test. The chromatograms of blank plasma/brain samples 
had been free of interference for the quantitation. Peak area at the retention interval of the 
target analyte did not exceed 25 % of the LLOQ (Lower Limit Of Quantitation) peak area. The 
signal to noise ratio was >5:1 for the analyte peak at LLOQ level. Calibration curves were 
generated and analysed as   the manufacturer’s recommendation using Thermo Xcalibur LC 
Quan software using 1/x as weighing factor. Calibration standards at the LLOQ level were 
not allowed to differ no more than 20% of nominal concentration, all other points in the 
calibration were allowed to differ less than 15%. 
 
Inclined screen test  (Suppl. Fig. 3) 
This test measures muscle tone, strength, and balance and was carried out in male NMRI 
mice. S 44819 (Nano F3; 3-100 mg/kg) or the reference compounds diazepam or baclofen 
(both 10-100 mg/kg) were administered acutely (in a volume of 10 ml/kg i.p.). Thirty min later 
each mouse was placed on a 33 cm x 52 cm, 1 cm x 1 cm square wire mesh panel that was 
tilted 60° to the horizontal plane of the floor. Five mice were tested simultaneously. ED50 was 
estimated by plotting log dose vs. the percentage of animals that had shown signs of muscle 
weakness (slipped or fell of the screen) during an observation period of 30 s from a total of 
10 mice receiving the same dose. 
Vogel test in rats (Suppl. Fig. 4 ) 
The test was as originally described by Vogel et al. (Vogel et al., 1971; Volk et al., 2011). 
Male SPRD rats were water-deprived for 24 h prior to being placed in the experimental 
chambers for 1 min and allowed to drink from the water-spout (habituation session). The 
animals were water-deprived and fasted for another 24 h. Following this second deprivation 
period, rats were treated either with vehicle solution or three doses of S44819 ( (nanoF3; 1 , 
3 and 10 mg/kg) acutely (in a volume of 2 ml/kg i.p.). Sixty min after treatment, animals were 
again placed in the chambers for 5.5 min for a test session, where after a 30 s grace period 
every completion of 20 consecutive licks on the water spout was punished by a 0.6 mA 
shock (0.6 s) to the tongue during the 5 min. The plastic chambers (19 x 19 x 17 cm), with 
metal grid floors were connected to a shock generator delivering an electric shock to the 
water spout located in the center of one of the walls 5 cm above the grid floor. Eight 
experimental chambers were connected to an IBM PC computer via a central unit 
(Experimetria Inc, Hungary). The number of licks and tolerated shocks were simultaneously 
recorded and stored in the computer. The number of tolerated shocks was evaluated. 
Diazepam (3 and 10 mg/kg) was used as positive control. 
Light-dark test in mice  (Suppl. Fig. 5 ) 
The male NMRI mice were placed in the test room for a day before the testing and they were 
deprived of food for approximately 12 h (Kapus et al., 2008; Volk et al., 2011). After 
intraperitoneal treatment (10 ml/kg), animals were kept in a cage during the pre-treatment 
time. After 30 min (Diazepam 3 mg/kg i.p.) or 1 h (S44819 nanoF3; 30 mg/kg i.p) pre-
treatment time, the treated animals were placed into the light-dark apparatus. The light-dark 
apparatus consisted of 7 Plexiglas cages (41 x 41 x 30 cm) divided into two compartments. 
The open compartment was open at the top made of transparent Plexiglas and brightly 
illuminated by an 85 W (Osram) tungsten bulb. The dark compartment was made of black 
Plexiglas and was covered at the top. A small opening connected the two compartments. 
Activity was measured automatically by interruptions of horizontal and vertical infrared 
beams (Omnitech Animal Activity Monitor, Omnitech Electronics Inc., Columbus, Ohio, USA). 
Mice were individually placed in the centre of the open compartment, facing away from the 
partition and allowed to explore the apparatus for 5 min. The horizontal activity and 
movement time in the light compartment were evaluated. 
 Elevated plus maze test in mice  (Suppl. Fig. 6 ) 
The test was adapted from the method of Lister (Kapus et al., 2008; Lister, 1987). Male 
NMRI mice were treated acutely with vehicle (vehicle group) or three doses of S44819 
(nanoF3; 3, 10 and 30mg/kg) or the reference compound Diazepam (3 mg/kg)) (in a volume 
of 10 ml/kg, i.p.). Sixty min after treatment the mice were placed in the central area of the 
plus maze. Animals were individually tested in the plus-maze. The plus maze had a matte 
black acrylic surface, and consisted of four arms (two open without walls and two enclosed 
by 15 cm high walls) each arm was 30 cm long and 5 cm wide and fixed-up 60 cm above 
floor. The behaviour of the animals in the maze was recorded by a video camera in an 
adjacent room for 5 min, and evaluated with the TSE VideoMot2 software (TSE Systems 
GmbH, Bad Homburg, Germany). The means ± S.E.M. of time spent by each mouse in the 
open arms and those of the number of open arm entries calculated in each group. 
Marble burying test in mice (Suppl. Fig. 7 ) 
Four doses of S 44819 (Aqoat; 1, 3, 10 and 30 mg/kg) or vehicle were administered orally to 
male NMRI mice in a volume of 20 ml/kg body weight. After 120 min the mice were placed 
individually into the experimental chamber which was a 22 x 16 x 14 cm Acrylic box with 
5 cm thick layer of sawdust on the bottom. Twenty-four glass marbles (16 mm in diameter) 
were placed in close contact on the sawdust in the middle of the cage. The mice were left in 
the cage with the marbles for 15 min after which they were removed and the number of 
marbles, that were covered more than two thirds by sawdust (i.e. buried), was counted. 
 
 
Forced swim test (Porsolt test) in mice (Suppl. Fig. 8 ) 
The test was conducted using a modification of the method of Porsolt et al. (Porsolt, 1981; 
Volk et al., 2011). Three doses of S 44819 (Aqoat; 3, 10 and 30 mg/kg), vehicle or reference 
venlafaxine (30 mg/kg) were administered orally to male C57BL/6J mice at a volume of 20 
ml/kg body weight. After 120 min the mice were placed individually into glass cylinders which 
were 25 cm high, 10 cm in diameter and contained 12 cm high water. The temperature of the 
water was 25 oC. Four mice were tested simultaneously. Duration of immobility was 
measured during the last 4 min of the 6 min testing period.  
Tail suspension test in mice (Suppl. Fig. 9 ) 
Automated TST device (TSE, Tail suspension System V 2.2, TSE System GmbH, Bad 
Homburg, Germany) was used to measure the total sum of periods of immobility and the 
force of movement of the mice. Three doses of S 44819 (S 44819 (Aqoat; 3, 3 and 10 
mg/kg),) or vehicle or reference venlafaxine were administered orally to the male C57BL/6J 
mice at a volume of 20 ml/kg body weight. Two hours later the mice were suspended by their 
tails using adhesive scotch tape, to a hook connected to a strain gauge (in a separate 
measuring box) that detected the movements of the mice and transmitted them to a central 
unit that calculated the total duration of immobility and amplitude (%) during a 6 min test. The 
maximal force provided by the apparatus is 300 pounds. The amplitude is the force produced 
by the mice which is expressed as % of maximal force. Mice were considered immobile if the 
force under 2.25 pounds measured by the apparatus. The sums of immobility time were 
evaluated by groups. 
Pentylenetetrazole-induced seizure threshold test in mice (Suppl. Fig. 10) 
The experiments were performed according to the method of Dawson et al. (Dawson et al., 
2006; Ling et al., 2015). Male NMRI mice were treated acutely with vehicle (vehicle group) or 
with three doses of S44819 (Nano F3; 3, 10 and 30 mg/kg) intraperitoneally (10 ml/kg) Thirty 
min after intraperitoneal administration, the mice were infused with pentylenetetrazole (PTZ) 
intravenously (i.v., 10 mg/ml solution, infusion rate 12 ml/h). A cannula attached to a 2 ml 
syringe prefilled with PTZ solution was used. For the purpose of infusion, the animal was 
restrained and needle was inserted into the tail vein. The accuracy of needle placement in 
the vein was confirmed by appearance of blood in the cannula. The animal was kept in a 
transparent Perspex box with holes for ventilation. The syringe was held in the adjustable 
motor driven infusion pump (Perfusor fm B. Braun Melsungen AG, Melsungen, Germany). In 
this way animal could move freely in the box without strain on the attached cannula with no 
severe struggling. PTZ was infused at a constant rate of 0.2 ml/min. During the infusion, mice 
were observed for the onset of different types of seizures by a trained observer who was 
blind to the treatment regimes. The time latencies from start of infusion to the appearance of 
first clonus (characterized by the rapid involuntary rhythmic contraction and relaxation of 
limbs) were recorded. Infusion was stopped at the appearance of clonic seizure in each 
animal and the corresponding administered dose of PTZ was calculated.  The non-selective 
GABAA negative allosteric modulator FG7142 (30 mg/kg, i.p.) was used as the reference 
compound.  
 
Statistical analysis 
The results were expressed as mean ± S.E.M. The statistical analysis was used with the 
GraphPad Prism 6.0 program (GraphPad Software, San Diego, USA). The data were 
analyzed by one-way analysis of variance (ANOVA) followed by a Dunnett’s post-hoc test for 
multiple comparisons. The test was validated by Student’s unpaired t-test between the 
control group and the group treated with the respective reference compound. P <0.05 was 
considered significant. 
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Supplementary  FIGURES 
 Suppl. Fig. 1 Time-course of the concentrations of S44819 in plasma and brain 
homogenates in male C57Bl/6 mice given 3 mg/kg p.o. S44819 Aqoat at time 0.  The 
insert shows the levels of S44819 in brain homogenates as a percentage of the 
plasma concentration from the same animals.  Results in C57BL/6J and NMRI mice 
were closely similar. Data are mean ± S.E.M. , n=3/point. A  non-GLP study.  
 
 
Suppl. Fig. 2 Concentrations of S44819 in blood plasma and brain of NMRI mice upon 
administration of various doses of formulated S 44918 p.o.  A) S 44819 nanoF3 at 60 min, B) 
S44819 Aqoat at 120 min.  Data are mean ± S.E.M., n=3/point in A and n=6/point in B. 
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 Suppl. Fig.3 Effect of S44819 in the inclined screen in male NMRI mice. Single points 
constructed from the observation of 10 mice per group are shown.  S44819 (nano F3), 
baclofen and diazepam were given i.p. 30 min before the start of the test.  Curves were fitted 
by constraining the minimum at 0 % and the maximum at 100 % with GraphPad Prism v6.0 
four-parameter non-linear regression. Data are mean ± S.E.M., Single points constructed 
from the observation of 10 mice per group are shown. 
 
 
 
Suppl. Fig. 4 Effect of S44819 in the Vogel conflict test in male SPRD rats. Data are mean ± 
S.E.M., n=8/group. Vehicle, S44819 (nano F3) and diazepam were given i.p. 60 min before 
the start of the test. ** P<0.01 vs vehicle, One-way ANOVA followed by Dunnett’s test. 
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  Suppl. Fig. 5 Effect of S44819 in the light-dark box paradigm in male NMRI mice. Data are 
mean ± S.E.M., n=10/group. Vehicle, S44819 (nano F3) and diazepam were given i.p. 60 
min before the start of the test, diazepam was given i.p. 30 min before the start of the test.  * 
P<0.05, One-way ANOVA followed by Dunnett’s test. 
  
 
Suppl. Fig. 6 Effect of  44819 in the elevated plus maze in male NMRI mice. Data are mean 
± S.E.M., n=9-10/group. Vehicle, S44819 (nano F3) were given i.p. 60 min before the start of 
the test, diazepam was given i.p. 30 min before the start of the test.  * P<0.05, *** P<0.001 vs 
vehicle, Student’s t-test. 
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 Suppl. Fig. 7 Effect of S44819 on marble burying activity in male NMRI mice. Data are 
mean ± S.E.M., n=8/group. Vehicle or S44819 (Aqoat) were given p.o. 120 min before the 
start of the test. No significant effect one-way ANOVA. 
 
Suppl. Fig. 8 Effect of S44819 in the Porsolt test (forced swimming) in male C57BL/6J mice. 
Data are mean ± S.E.M., n=12/group. Vehicle, S44819 (Aqoat) and venlafaxine were given 
p.o. 120 min before the start of the test, ***P<0.001 vs. control,  Student’s t-test), No 
significant effect of S44819 (one-way ANOVA). 
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Suppl. Fig.9 Effect of  S44819 in the tail suspension test in male C57BL/6J mice. Data are 
mean ± S.E.M., n=12/group. Vehicle, S44819 (Aqoat) and venlafaxine were given p.o. 120 
min before the start of the test.  ***P<0.001 vs. control, Student’s t-test), No significant effect 
of S44819 (one-way ANOVA). 
 
 
Suppl. Fig. 10 Effect of S 44819 on the pentylenetetrazole (PTZ) convulsion threshold. Data 
are mean ± S.E.M., n=10/group.  Vehicle, S44819 (nano F3) and FG-7142 were given i.p. 60 
min before the start of the intravenous infusion of pentylenetetrazol. ** P<0.01 vs. vehicle, 
Student’s t-test. No significant effect of S44819 (one-way ANOVA). 
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Suppl. Fig.11 Diagrammatic scheme of the experimental protocol of the fear-potentiated 
startle response test.  
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